[go: up one dir, main page]

PE20161327A1 - Proteinas de enlace al antigeno il-23 humana - Google Patents

Proteinas de enlace al antigeno il-23 humana

Info

Publication number
PE20161327A1
PE20161327A1 PE2016002001A PE2016002001A PE20161327A1 PE 20161327 A1 PE20161327 A1 PE 20161327A1 PE 2016002001 A PE2016002001 A PE 2016002001A PE 2016002001 A PE2016002001 A PE 2016002001A PE 20161327 A1 PE20161327 A1 PE 20161327A1
Authority
PE
Peru
Prior art keywords
antigen
human
binding proteins
antibody
refers
Prior art date
Application number
PE2016002001A
Other languages
English (en)
Inventor
Heather Cerne
Janet D Cheng
Randal R Ketchem
Yu Zhang
Derek Evan Piper
Yu Sun
Jennifer E Towne
Jason Charles O'neill
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43413789&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20161327(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of PE20161327A1 publication Critical patent/PE20161327A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se refiere a una proteina de enlace al antigeno tal como un anticuerpo que se enlaza a IL-23. Tambien se refiere a una composicion farmaceutica de dicho anticuerpo que es util en el tratamiento de esclerosis multiple, artritis reumatoide, cancer y psoriasis, entre otros
PE2016002001A 2009-10-26 2010-10-26 Proteinas de enlace al antigeno il-23 humana PE20161327A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25498209P 2009-10-26 2009-10-26
US38128710P 2010-09-09 2010-09-09

Publications (1)

Publication Number Publication Date
PE20161327A1 true PE20161327A1 (es) 2016-12-03

Family

ID=43413789

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2012000564A PE20121579A1 (es) 2009-10-26 2010-10-26 Proteinas de enlace al antigeno il-23 humanas
PE2016002001A PE20161327A1 (es) 2009-10-26 2010-10-26 Proteinas de enlace al antigeno il-23 humana

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2012000564A PE20121579A1 (es) 2009-10-26 2010-10-26 Proteinas de enlace al antigeno il-23 humanas

Country Status (39)

Country Link
US (9) US8722033B2 (es)
EP (3) EP2493925B1 (es)
JP (5) JP5930968B2 (es)
KR (3) KR20160118278A (es)
CN (3) CN104761642A (es)
AR (1) AR078778A1 (es)
AU (1) AU2010315557B2 (es)
BR (2) BR122020002402B8 (es)
CA (2) CA3030092C (es)
CL (1) CL2012001096A1 (es)
CO (1) CO6531481A2 (es)
CR (1) CR20120210A (es)
CY (1) CY1118576T1 (es)
EA (1) EA025366B1 (es)
ES (1) ES2613236T3 (es)
HK (2) HK1177469A1 (es)
HR (1) HRP20170037T1 (es)
HU (1) HUE030871T2 (es)
IL (3) IL219241A (es)
JO (1) JO3244B1 (es)
LT (1) LT2493925T (es)
MA (1) MA33757B1 (es)
MX (1) MX358249B (es)
MY (1) MY156286A (es)
NZ (2) NZ625630A (es)
PE (2) PE20121579A1 (es)
PH (1) PH12012500771A1 (es)
PL (1) PL2493925T3 (es)
PT (1) PT2493925T (es)
RS (1) RS55666B1 (es)
SG (2) SG10201800682SA (es)
SI (1) SI2493925T1 (es)
SM (1) SMT201700069T1 (es)
TN (1) TN2012000167A1 (es)
TW (2) TW201417830A (es)
UA (1) UA113609C2 (es)
UY (1) UY32971A (es)
WO (1) WO2011056600A1 (es)
ZA (1) ZA201203058B (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
JP6496481B2 (ja) * 2011-01-25 2019-04-03 モネル ケミカル センシズ センターＭｏｎｅｌｌ Ｃｈｅｍｉｃａｌ Ｓｅｎｓｅｓ Ｃｅｎｔｅｒ 甘味を提供若しくは調整するための組成物および方法ならびにそれらのスクリーニング方法
EP2583979B1 (en) * 2011-10-19 2015-12-16 Effimune Methods to prepare antibodies directed against p19 subunit of human IL-23
PL3326649T3 (pl) * 2012-05-03 2022-04-25 Boehringer Ingelheim International Gmbh Przeciwciała anty-il-23p19
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
EA201591581A1 (ru) 2013-03-15 2016-01-29 Амген Инк. Способы лечения псориаза при помощи анти-il-23 антитела
AP2015008801A0 (en) 2013-03-15 2015-10-31 Amgen Inc Methods for treating crohn's disease using an anti-il23 antibody
CN110658337B (zh) 2013-10-21 2023-06-16 武田药品工业株式会社 自身免疫性疾病的诊断和治疗
AU2015247742A1 (en) 2014-04-15 2016-11-24 Sorrento Therapeutics, Inc. Antigen binding proteins that bind WISP1
EP3149049B1 (en) * 2014-05-27 2022-10-26 The University Of Queensland Il-22 for use in treating metabolic disorders
MX2017000527A (es) 2014-07-14 2017-08-10 Amgen Inc Formulaciones de anticuerpos cristalinos.
JP2017524359A (ja) 2014-07-24 2017-08-31 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｉｌ−２３ａ関連疾患の処置に有用なバイオマーカー
MY192824A (en) 2014-09-03 2022-09-12 Boehringer Ingelheim Int Compound targeting il-23a and tnf-alpha and uses thereof
CA2998349A1 (en) 2015-09-17 2017-03-23 Amgen Inc. Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
TWI811716B (zh) * 2015-09-18 2023-08-11 德商百靈佳殷格翰國際股份有限公司 治療發炎性疾病之方法
EP3365685B1 (en) * 2015-10-19 2020-11-25 Dyax Corp. Immunoassay to detect cleaved high molecular weight kininogen
EP3393515A4 (en) 2015-12-22 2019-08-14 Amgen Inc. CCL20 AS A PREDICTOR FOR CLINICAL RESPONSE TO IL23 ANTAGONISTS
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2019023812A1 (en) * 2017-08-04 2019-02-07 The Hospital For Sick Children VACCINE COMPOSITION AGAINST MALARIA AND METHOD THEREOF
EP4074734A1 (en) * 2017-08-04 2022-10-19 The Hospital for Sick Children Nanoparticle platform for antibody and vaccine delivery
TWI837532B (zh) 2018-03-30 2024-04-01 美商美國禮來大藥廠 治療潰瘍性結腸炎之方法
EA202190197A1 (ru) * 2018-07-13 2021-04-26 Астразенека Коллаборэйшн Венчерз, Ллс Лечение язвенного колита с помощью бразикумаба
GB201820687D0 (en) * 2018-12-19 2019-01-30 Kymab Ltd Antagonists
EP3980065A4 (en) * 2019-06-04 2023-07-05 Janssen Biotech, Inc. SAFE AND EFFECTIVE METHOD OF TREATMENT OF PSORIAL ARTHRITIS WITH ANTI-IL23 SPECIFIC ANTIBODY
TW202108629A (zh) * 2019-06-26 2021-03-01 圓祥生命科技股份有限公司 用於t細胞活化之抗體
KR20220143005A (ko) 2019-12-20 2022-10-24 노바록 바이오테라퓨틱스 리미티드 항-인터루킨-23 p19 항체 및 이의 사용 방법
CN111718414B (zh) * 2020-06-12 2021-03-02 江苏荃信生物医药有限公司 抗人白介素23单克隆抗体及其应用
WO2022041390A1 (zh) * 2020-08-28 2022-03-03 江苏荃信生物医药股份有限公司 包含高浓度抗人白介素23单克隆抗体的低粘度液体制剂及其制备方法
TW202428304A (zh) 2020-09-10 2024-07-16 美商美國禮來大藥廠 治療性抗體調配物
CN112625129B (zh) * 2020-11-26 2022-05-20 江苏荃信生物医药股份有限公司 一种抗人白介素23及包含其的试剂盒及其检测方法
US20220373539A1 (en) * 2021-05-24 2022-11-24 Amgen Inc. Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
KR20240025524A (ko) * 2021-06-25 2024-02-27 상가모 테라퓨틱스, 인코포레이티드 Il-23r에 특이적인 항원 결합제 및 이의 용도
EP4409298A1 (en) 2021-09-30 2024-08-07 Eli Lilly and Company Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis
CN114994331B (zh) * 2022-05-17 2023-02-24 无锡科金生物科技有限公司 一种检测蛋白表达水平的试剂盒及其制备方法和应用
WO2024077113A1 (en) 2022-10-06 2024-04-11 Eli Lilly And Company Methods of treating fatigue in ulcerative colitis

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
WO1987005330A1 (en) 1986-03-07 1987-09-11 Michel Louis Eugene Bergh Method for enhancing glycoprotein stability
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5457038A (en) 1988-11-10 1995-10-10 Genetics Institute, Inc. Natural killer stimulatory factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6683046B1 (en) 1989-12-22 2004-01-27 Hoffmann-La Roche Inc. Purification and characterization of cytotoxic lymphocyte maturation factor and monoclonal antibodies thereto
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69127627T2 (de) 1990-08-29 1998-02-19 Genpharm Int Produktion und Nützung nicht-menschliche transgentiere zur Produktion heterologe Antikörper
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU2249592A (en) 1991-06-14 1993-01-12 Dnx Corporation Production of human hemoglobin in transgenic pigs
WO1993001227A1 (en) 1991-07-08 1993-01-21 University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
ATE288484T1 (de) 1991-11-14 2005-02-15 Charles Weissmann Transgene nicht-menschliche tiere ohne prionprotein
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
JPH07509137A (ja) 1992-07-24 1995-10-12 セル　ジェネシス，インク． 異種抗体の生産
CA2146559A1 (en) 1992-10-23 1994-05-11 Melanie K. Spriggs Methods of preparing soluble, oligomeric proteins
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
JP4215172B2 (ja) 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
ZA986596B (en) 1997-07-25 1999-02-08 Schering Corp Mammalian cytokine related reagents
US6060284A (en) 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
EP1074268B1 (en) 1998-03-17 2008-01-16 Chugai Seiyaku Kabushiki Kaisha Preventives or remedies for inflammatory intestinal diseases containing il-6 receptor antagonist antibodies
EP1072610B1 (en) 1998-04-14 2010-07-21 Chugai Seiyaku Kabushiki Kaisha Novel cytokine-like protein
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7883704B2 (en) 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US7090847B1 (en) 1999-09-09 2006-08-15 Schering Corporation Mammalian cytokines; related reagents and methods
JP4505166B2 (ja) 1999-09-09 2010-07-21 シェーリング コーポレイション 哺乳動物インターロイキン−１２ｐ４０およびインターロイキンｂ３０、その組成物、抗体、薬学的組成物における使用
CN101824088B (zh) 2002-10-30 2012-05-30 健泰科生物技术公司 Il-17产生的抑制
ATE515514T1 (de) 2002-12-23 2011-07-15 Schering Corp Verwendungen von säuger-cytokin il-23 ; verwandte reagenzien
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
CA2518262C (en) 2003-03-10 2014-05-06 Schering Corporation Uses of il-23 agonists and antagonists; related reagents
CN101052726A (zh) 2003-05-09 2007-10-10 森托科尔公司 IL－23p40特异性免疫球蛋白衍生蛋白、组合物、方法和用途
US20050287593A1 (en) 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
CA2565566A1 (en) 2004-05-03 2005-11-17 Schering Corporation Use of il-17 expression to predict skin inflammation; methods of treatment
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
US7820168B2 (en) 2004-12-20 2010-10-26 Schering Corporation Treatment of diabetes using antibodies to IL-23, IL-23 receptor and IL-17
SG158150A1 (en) 2004-12-21 2010-01-29 Centocor Inc Anti-il-12 antibodies, epitopes, compositions, methods and uses
EP1907421A4 (en) 2005-06-30 2012-03-28 Abbott Lab IL-12 / P40 BINDING PROTEINS
CN101252951B (zh) 2005-06-30 2011-12-21 森托科尔公司 抗il-23抗体、组合物、方法和用途
ES2347690T3 (es) 2005-08-25 2010-11-03 Eli Lilly And Company Anticuerpos anti-il-23.
CA2620802A1 (en) * 2005-08-31 2007-03-08 Schering Corporation Engineered anti-il-23 antibodies
CN1955248B (zh) 2005-10-28 2011-10-12 安集微电子（上海）有限公司 钽阻挡层用化学机械抛光浆料
US20090270480A1 (en) 2005-12-28 2009-10-29 Bernard Amegadzie Markers and Methods for Assessing and Treating Psoriasis and Related Disorders
ES2517420T3 (es) * 2005-12-29 2014-11-03 Janssen Biotech, Inc. Anticuerpos anti-IL-23 humanos, composiciones, procedimientos y usos
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
EP2044118A2 (en) 2006-06-13 2009-04-08 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
AU2008205512B2 (en) * 2007-01-16 2014-06-12 Abbvie Inc. Methods for treating psoriasis
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
PL2059534T3 (pl) 2007-02-23 2012-09-28 Merck Sharp & Dohme Przeciwciała Anty-IL-23p19 wytworzone metodą inżynierii genetycznej
US20100111966A1 (en) * 2007-02-23 2010-05-06 Schering Corporation Engineered anti-il-23p19 antibodies
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
EP2215125A1 (en) 2007-11-27 2010-08-11 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
WO2009117289A2 (en) 2008-03-18 2009-09-24 Abbott Laboratories Methods for treating psoriasis
KR101781965B1 (ko) 2008-08-14 2017-09-27 테바 파마슈티컬즈 오스트레일리아 피티와이 엘티디 항-ｉｌ-12/ｉｌ-23 항체
AU2009288419B2 (en) 2008-08-27 2015-08-06 Merck Sharp & Dohme Llc Lyophilized formulatons of engineered anti-IL-23p19 antibodies
CA2757237A1 (en) 2009-04-01 2010-10-14 Jane Elizabeth Clarkson Anti-il-23 immunoglobulins
US20120027799A1 (en) 2009-04-02 2012-02-02 The Johns Hopkins University Compositions and methods for treating or preventing inflammatory bowel disease and colon cancer
EP2435480A1 (en) 2009-05-27 2012-04-04 Ablynx N.V. Biparatopic protein constructs directed against il-23
IN2012DN01965A (es) 2009-09-14 2015-08-21 Abbvie Deutschland
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
BR112012017150B1 (pt) 2010-01-15 2022-03-03 Kirin-Amgen Inc Formulação farmacêutica, recipiente farmacêutico, e kit
EA201270713A1 (ru) 2010-02-18 2013-01-30 Бристол-Майерс Сквибб Компани Белки на основе фибронектина с каркасными доменами, которые связывают ил-23
MX341309B (es) 2010-07-20 2016-08-12 Cephalon Australia Pty Ltd Anticuerpos especificos del heterodimero de anti-il-23.
US20120189637A1 (en) 2010-10-06 2012-07-26 Valdes Joaquin Mario Methods for treating psoriasis
DK2625199T3 (en) 2010-10-08 2018-02-26 Novartis Ag Method of treating psoriasis using IL-17 antagonists
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
EP2661448A4 (en) 2011-01-07 2015-09-16 Abbvie Inc ANTI-IL-12 / IL-23 ANTIBODIES AND USES THEREOF
AP2015008801A0 (en) 2013-03-15 2015-10-31 Amgen Inc Methods for treating crohn's disease using an anti-il23 antibody
CA2998349A1 (en) 2015-09-17 2017-03-23 Amgen Inc. Prediction of clinical response to il23-antagonists using il23 pathway biomarkers
EP3393515A4 (en) 2015-12-22 2019-08-14 Amgen Inc. CCL20 AS A PREDICTOR FOR CLINICAL RESPONSE TO IL23 ANTAGONISTS
EA202190197A1 (ru) 2018-07-13 2021-04-26 Астразенека Коллаборэйшн Венчерз, Ллс Лечение язвенного колита с помощью бразикумаба
JP2022544992A (ja) 2019-08-21 2022-10-24 アストラゼネカ・コラボレイション・ベンチャーズ・リミテッド・ライアビリティ・カンパニー クローン病を治療するためのブラジクマブの使用

Also Published As

Publication number Publication date
BR122020002402B1 (pt) 2022-02-08
US9951129B2 (en) 2018-04-24
IL219241A0 (en) 2012-06-28
BR112012009854B8 (pt) 2021-05-25
KR101652609B1 (ko) 2016-08-30
US9487580B2 (en) 2016-11-08
HK1212357A1 (en) 2016-06-10
US20220056122A1 (en) 2022-02-24
PT2493925T (pt) 2017-02-14
US12012449B2 (en) 2024-06-18
AU2010315557A1 (en) 2012-09-20
TW201121567A (en) 2011-07-01
RS55666B1 (sr) 2017-06-30
IL244801A0 (en) 2016-04-21
KR20120090091A (ko) 2012-08-16
BR112012009854B1 (pt) 2020-12-15
KR20140062186A (ko) 2014-05-22
TWI432210B (zh) 2014-04-01
MX2012004868A (es) 2012-08-03
KR101568461B1 (ko) 2015-11-12
SI2493925T1 (sl) 2017-05-31
UA113609C2 (xx) 2017-02-27
TW201417830A (zh) 2014-05-16
US20200181255A1 (en) 2020-06-11
HRP20170037T1 (hr) 2017-03-10
JP2020018308A (ja) 2020-02-06
US20130004501A1 (en) 2013-01-03
PE20121579A1 (es) 2012-12-13
NZ599875A (en) 2014-10-31
LT2493925T (lt) 2017-04-25
US20140212428A1 (en) 2014-07-31
US20210024626A1 (en) 2021-01-28
US20190071498A1 (en) 2019-03-07
TN2012000167A1 (en) 2013-12-12
IL274871A (en) 2020-07-30
WO2011056600A1 (en) 2011-05-12
JP7023908B2 (ja) 2022-02-22
US8722033B2 (en) 2014-05-13
BR112012009854A2 (pt) 2016-11-22
KR20160118278A (ko) 2016-10-11
UY32971A (es) 2010-11-30
JP2013507991A (ja) 2013-03-07
JP5930968B2 (ja) 2016-06-08
HK1177469A1 (en) 2013-08-23
PH12012500771A1 (en) 2012-11-26
IL244801B (en) 2020-05-31
CA3030092A1 (en) 2011-05-12
ZA201203058B (en) 2013-01-30
CL2012001096A1 (es) 2012-09-28
JP2022033730A (ja) 2022-03-02
BR122020002402B8 (pt) 2022-03-29
PL2493925T3 (pl) 2017-09-29
MA33757B1 (fr) 2012-11-01
CN102741285B (zh) 2015-03-25
ES2613236T3 (es) 2017-05-23
EP2493925A1 (en) 2012-09-05
IL219241A (en) 2016-03-31
AU2010315557B2 (en) 2014-02-27
MY156286A (en) 2016-01-29
EP2493925B1 (en) 2016-11-23
US20170002070A1 (en) 2017-01-05
SG10201800682SA (en) 2018-03-28
US20190322737A1 (en) 2019-10-24
CN102741285A (zh) 2012-10-17
HUE030871T2 (en) 2017-06-28
JP2018117626A (ja) 2018-08-02
EA025366B1 (ru) 2016-12-30
SG10202103260TA (en) 2021-05-28
EA201270571A1 (ru) 2012-09-28
CY1118576T1 (el) 2017-07-12
CO6531481A2 (es) 2012-09-28
CR20120210A (es) 2012-07-20
EP3181586A1 (en) 2017-06-21
AR078778A1 (es) 2011-11-30
BR112012009854A8 (pt) 2019-10-08
SMT201700069T1 (it) 2017-05-08
CN110407936A (zh) 2019-11-05
CA2778112A1 (en) 2011-05-12
MX358249B (es) 2018-08-10
US20210230267A1 (en) 2021-07-29
CA2778112C (en) 2019-02-26
CN104761642A (zh) 2015-07-08
EP3656790A1 (en) 2020-05-27
JP2016102122A (ja) 2016-06-02
JO3244B1 (ar) 2018-03-08
CA3030092C (en) 2023-12-19
JP7278355B2 (ja) 2023-05-19
NZ625630A (en) 2016-09-30

Similar Documents

Publication Publication Date Title
PE20161327A1 (es) Proteinas de enlace al antigeno il-23 humana
CL2012000524A1 (es) Anticuerpo humanizado que se une a cdcp1 humana útil en el tratamiento del cáncer; composición farmacéutica; ácido nucleico, vector de expresión y célula huésped que lo comprende; y método para producir el anticuerpo.
PE20142243A1 (es) Anticuerpos que se unen a ox40 y sus usos
PE20170772A1 (es) Anticuerpo monoclonal anti-ctla4 o su fragmento de union a antigeno, una composicion farmaceutica y uso
CL2011002482A1 (es) Anticuerpo biespecificos que se une especificamente a las proteinas erbb-3 humana y c-met humana; acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar cancer
EA201300256A1 (ru) Антитела к рецептору эпидермального фактора роста-3 (her3)
MX382398B (es) Proteinas de union a antigeno st2.
PE20170288A1 (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno
EA201291039A1 (ru) Антитела, связывающие cd27 человека, и их применение
EA201270769A1 (ru) Антитела к cgrp
CL2008002444A1 (es) Anticuerpo o fragmento del mismo que se une a la proteina c-fms humana; molecula de acido nucleico que la codifica; vector y celula huesped; metodo de elaboracion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir una condicion asociada con c-fms en un paciente.
PE20140633A1 (es) Anticuerpos neutralizadores anti-ccl20
PE20131209A1 (es) Anticuerpos anti-fap
MX2011011754A (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b.
ECSP14001260A (es) Inmunoligantes biespecificos dirigidos contra tnf e il-17 referencia cruzada a solicitudes relacionadas
CL2013001279A1 (es) Anticuerpo humano aislado o fragmento de union a antigeno del mismo que se une especificamente y neutraliza la actividad del ligando 1a de tipo tnf humano (htl1a); molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica que lo comprende; y su uso.
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
CL2012000914A1 (es) Anticuerpos monoclonales que se unen especificamente a la region c-terminal de progastrina. uso para la preparacion de un medicamento util en el tratamiento de cancer colorectal.
EA201591611A1 (ru) Конъюгаты антитело-лекарственное средство
EA201790664A1 (ru) Антитела против мезотелина и иммуноконъюгаты
UA115439C2 (uk) Гуманізоване антитіло, яке розпізнає альфа-синуклеїн
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
CL2011002831A1 (es) Anticuerpo humanizado especifico de la forma protofibrilar del peptido a-beta; uso de dicho anticuerpo para tratar transtornos neurodegenerativos; composicion farmaceutica; celula que produce dichos anticuerpos; y procedimientos de preparacion de dicho anticuerpo.
UA114712C2 (uk) Моноклональне антитіло, яке імуноспецифічно зв'язується з людським psgl-1, та його застосування
EA201690503A1 (ru) Антитела

Legal Events

Date Code Title Description
FA Abandonment or withdrawal